Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 808.30
Change Today -21.90 / -2.64%
Volume 56.0K
PLX On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
Tel Aviv
As of 10:24 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

protalix biotherapeutics inc (PLX) Snapshot

Open
$821.00
Previous Close
$830.20
Day High
$821.00
Day Low
$800.30
52 Week High
05/11/14 - $1,430
52 Week Low
12/30/14 - $668.80
Market Cap
755.8M
Average Volume 10 Days
101.5K
EPS TTM
--
Shares Outstanding
93.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTALIX BIOTHERAPEUTICS INC (PLX)

protalix biotherapeutics inc (PLX) Related Businessweek News

No Related Businessweek News Found

protalix biotherapeutics inc (PLX) Details

Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company’s product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-106, an oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and PRX-112, an orally administered glucocerebrosidase enzyme (GCD) for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD produced and encapsulated within carrot cells. Its product pipeline also comprises PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.

234 Employees
Last Reported Date: 03/12/15
Founded in 1993

protalix biotherapeutics inc (PLX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $93.7K
Founder and Executive Vice President of Resea...
Total Annual Compensation: $395.5K
Chief Financial Officer, Vice President, Secr...
Total Annual Compensation: $524.1K
Chief Operating Officer
Total Annual Compensation: $283.7K
Senior Vice President of Product Development
Total Annual Compensation: $348.9K
Compensation as of Fiscal Year 2014.

protalix biotherapeutics inc (PLX) Key Developments

Protalix BioTherapeutics, Inc. Reports Consolidated Financial Results for the Year Ended December 31, 2014

Protalix BioTherapeutics, Inc. reported consolidated financial results for the year ended December 31, 2014. For the year, the company reported revenues of $13,651,000 against $10,479,000 a year ago. Operating loss was $25,204,000 against $27,116,000 a year ago. Financial income was $196,000 against $391,000 a year ago. Net loss for the year was $29,943,000 against $27,790,000 a year ago. Net loss per share of common stock – basic and diluted was $0.32 against $0.30 a year ago.

Protalix BioTherapeutics, Inc. Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry Disease

Protalix BioTherapeutics, Inc. announced that the Company has completed enrollment in its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. All patients that completed the trial have opted to continue to receive PRX-102 in an open-label extension trial. PRX-102 is a proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme that is designed to be a more stable enzyme than currently marketed enzyme replacement therapies for Fabry disease. Additionally, the Company expects to report interim results from the 1mg/kg cohort in the third quarter of 2015, and full top-line results from all dosing cohorts in the fourth quarter of 2015. Management will request an end of Phase II meeting with the U.S. Food and Drug Administration in the fourth quarter of 2015, and anticipates initiating a phase III pivotal trial in early 2016. The phase I/II clinical trial of PRX-102 is an open-label, dose-ranging study treating 18 na¯ve male and female patients with Fabry disease. The three dose cohorts include dosage groups of 0.2 mg/kg, 1mg/kg and 2mg/kg with intravenous infusions of PRX-102 every two weeks, with a six-month efficacy follow up period.

Protalix BioTherapeutics, Inc. Reports Positive Interim Data from Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. announced positive interim efficacy and safety data from the Company’s ongoing phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. PRX-102 demonstrated meaningful clinical benefits across the following key disease parameters already in the low dose of 0.2 mg/kg: major reduction in Gb3 in Renal Peritubular Capillaries, significant improvement in all pain parameters, stabilization of cardiac and kidney function with favorable trends and low level of antibody formation. The phase I/II clinical trial of PRX-102 for the treatment of Fabry disease is an open-label, dose-ranging study treating up to 18 naïve male and female patients. The three dose cohorts include dosage groups of 0.2 mg/kg, 1 mg/kg and 2 mg/kg with intravenous infusions of PRX-102 every two weeks, with a six-month efficacy follow up period. The interim efficacy analysis includes 6 patients enrolled in the 0.2 mg/kg dose group at six months of treatment (for Gb3 in renal peritubular capillaries n=5). The interim safety analysis includes 12 patients; 6 patients enrolled in the 0.2 mg/kg dose group and 6 patients enrolled in the 1 mg/kg dose group. Based on an analysis of kidney biopsies with randomized blinded scoring, PRX-102 demonstrated a reduction in renal peritubular capillary Gb3 of 82.2% for males and 65.4% for females using a quantitative Barisoni Lipid Inclusion Scoring System (BLISS) for a combined reduction of 75.5%. Applying the semi quantitative scoring method, commonly used by approved enzyme replacement therapies, PRX-102 demonstrated a reduction of 69.6% in abnormal capillary score. Using the well-accepted Brief Pain Inventory scale, a 100% reduction in Worst Pain and an average of 78.8% improvement on patients’ Impact On Functioning were observed. Furthermore, all patients had stable cardiac function, with favorable trends after only six months, as measured by left ventricular mass (LVM), left ventricular mass index (LVMI) and ejection fraction (EF). Stable kidney function was also observed, with favorable trends after only six months, as measured by estimated glomerular filtration rate (eGFR) and urine protein. The safety analysis for adverse events represents a total of 6.7 patient years. PRX-102 was well tolerated, with the majority of events being mild and moderate. Only one of the 12 patients evaluated for safety experienced hypersensitivity. Six patients receiving the 0.2 mg/kg dose and 2 patients receiving the 1 m/kg dose were evaluated for antibody formation. Of these 8 patients, only 2 patients, or 33% of the 0.2 mg/kg dose cohort, developed antibodies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLX:IT 808.30 -21.90

PLX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PLX.
View Industry Companies
 

Industry Analysis

PLX

Industry Average

Valuation PLX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTALIX BIOTHERAPEUTICS INC, please visit www.protalix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.